Please login to the form below

Sprycel

This page shows the latest Sprycel news and features for those working in and with pharma, biotech and healthcare.

and leukaemia drug Sprycel (dasatinib) which brought in $558m, also up 14%.

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

There were also new indications approved for UCB’s Cimzia (certolizumab pegol), Amgen’s Prolia (denosumab), BMS’ Sprycel (dasatinib) and Yervoy (ipilimumab), Pfizer’s Xeljanz (tofacitinib), and Novo Nordisk’s Xultophy
NICE backs BMS leukaemia drug Sprycel

Overturning its former ruling against the oral therapy, NICE recommended Sprycel in final guidance for first- and second-line treatment of adults with CML. ... BMS has now agreed a patient access scheme for Sprycel, which brought in sales of $472m this
Opdivo drives gain in BMS sales, but business revamp coming

BMS' other growth products also contributed to the sales gains, with melanoma drug Yervoy (ipilimumab) rising 19% to $285m and Sprycel (dasatinib) for leukaemia up 15% to $472m.
England's Cancer Drugs Fund: Fixing a broken system

Bristol-Myers Squibb's Sprycel (dasatinib):. for treatment of lymphoid blast crisis chronic myeloid leukamia.
Pharma condemns Cancer Drugs Fund cuts

Bristol-Myers Squibb. Sprycel (dasatinib). Chronic myeloid leukaemia. Eisai. Halaven (eribulin). Breast cancer.

More from news
Approximately 4 fully matching, plus 27 partially matching documents found.

Interview: Harvey Berger and Timothy Clackson, Ariad

recommended for use in patients who have grown resistance to Tasigna (nilotinib) and Gleevec/Glivec (imatinib mesylate) from Novartis and Bristol-Myers Squibb's Sprycel (dasatinib). ... The drug was then developed with the specific intention of
Intellectual property threats in the BRIC markets

of the compulsory licence process for Herceptin, Sprycel and Ixempra, revocation of a patent for Pfizer's Sutent and a legal ruling allowing a generic version of Tarceva.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Add my company

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...